Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme, a biotechnology company, has announced that the FDA has granted marketing approval for Synvisc-One, a product intended for the relief of pain associated with osteoarthritis of the knee.
Subscribe to our email newsletter
According to Genzyme, Synvisc-One is the only single-injection viscosupplement approved for the treatment of osteoarthritis knee pain in the US. It is also approved in the EU and a number of Asian and Latin American countries. Genzyme will begin making Synvisc-One available immediately.
Ann Merrifield, president of Genzyme Biosurgery, the business unit of Genzyme, said: “Synvisc-One is an important therapy for osteoarthritis of the knee because it delivers long-term pain relief through a single injection without the systemic side effects that can be caused by steroids and anti-inflammatory medication. We expect that the approval of Synvisc-One will be a significant growth driver for the Synvisc franchise.”